Galmed Pharmaceuticals Ltd. Given Average Recommendation of Hold by Analysts
GLMD Stock | USD 2.88 0.17 5.57% |
About 65% of Galmed Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Galmed Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Galmed Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Galmed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Galmed |
Galmed Pharmaceuticals Ltd. has been assigned an average rating of Hold from the six analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. Separately, StockNews.com assumed coverage on shares of Galmed Pharmaceuticals
Read at thelincolnianonline.com
Galmed Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Galmed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Galmed Pharmaceuticals Fundamental Analysis
We analyze Galmed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Galmed Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Galmed Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Galmed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Galmed Pharmaceuticals Related Equities
MBIO | Mustang Bio | 5.26 | ||||
LPTX | Leap Therapeutics | 4.43 | ||||
ADAP | Adaptimmune Therapeutics | 3.23 | ||||
MREO | Mereo BioPharma | 1.58 | ||||
ABEO | Abeona Therapeutics | 1.01 | ||||
ADVM | Adverum Biotechnologies | 0.68 | ||||
KOD | Kodiak Sciences | 1.48 | ||||
PDSB | PDS Biotechnology | 2.28 | ||||
PIRS | Pieris Pharmaceuticals | 2.35 | ||||
FBIO | Fortress Biotech | 2.83 | ||||
ACHL | Achilles Therapeutics | 2.86 | ||||
AFMD | Affimed NV | 2.93 | ||||
AKBA | Akebia Ther | 3.03 | ||||
FBIOP | Fortress Biotech | 3.32 | ||||
APTO | Aptose Biosciences | 5.26 |
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |